

References

Afdhal NH, Dieterich DT and Pockros PJ et al.,(2004): Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. *Gastroenterology*;126:1302-1311.

Afdhal NH, Klopfer A and Tang L et al.,(2003): Hemoglobin increase is independently associated with increased health-related quality of life in anemic interferon/ribavirin-treated hepatitis C virus-infected patients treated with epoetin alfa. *Hepatology*; 38(suppl 1): 312A. Abstract.

Agnello V, Chung RT and Kaplan LM (1992): A role for hepatitis C virus infection in type II cryoglobulinemia. *N Engl J Med* ;327:1490-1495.

Alavian SM, Behnava B, Tabatabaei SV et al., (2010) The Comparative Efficacy and Safety of Peginterferon Alpha-2a vs 2b. alfa-2b plus ribavirin compared with interferon alfa-2b plus Ribavirin. *Gastroenterology*;138:126–132.

Allander T, Gruber A and Naghavi M (1995): Frequent patient to patient transmission of hepatitis C Virus in a hematology ward. *Lancet*; 345 (8950): 603-607.

Alter MJ (2003): Epidemiology and prevention of hepatitis B. *Semin Liver Dis*; 23 (1): 39–46.

Alter MJ (2006): The epidemiology of viral hepatitis and HIV co infection. Journal of hepatology ;44:56-59.

Andrade, L J.; Atta, A M.; Junior, A D.; et al (2008): Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin . A review Braz J Infect Dis., 12 (2): S1413.

Armstrong GL , Walsey A , simard EP et al.,(2006): The prevalence of hepatitis C virus infection in USA. Ann of Intern med; 144:705-714.

ASCIONE ET , MASSIMO DE LUCA, TARTAGLIONE et al., (2010): Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection. Gastroenterology;138:116–122.

Awad T, Kristian T , Goran H , et al., (2010): Peginterferon alpha-2a Is Associated with Higher Sustained Virological Response than Peginterferon alfa-2b in Chronic Hepatitis C: Systematic Review of Randomized Trials Hepatology;(51):726-742 the Treatment of Chronic HCV Infection: A Meta-Analysis. Hepat Mon;10(2):121-31.

Bartenschlager R and Lohmann V (2000): Replication of hepatitis C virus Gen .Virol 81:1631-1637.

Bennett CL, Silver SM and Djulbegovic B, et al(2008): Venous Thromboembolism and Mortality Associated With Recombinant

Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia. JAMA;299(8):914-24.

Berg T, von Wagner M and Nasser Set et al ., (2006): Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology;130:1086-1097.

Bonacini M and Puoti M (2000): Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Intern Med ;160(22):3365-73.

Booth J ,O'Grady J and Neuberger J (2001): Clinical guidelines of the management of hepatitis C .Gut ;49 (Suppl I):1-21.

Breesters D, Cuypers H and Winkel I (1994): Storage conditions of blood samples and primer selection affect yield of cDNA polymerase chain reaction products of hepatitis C virus . Clin Microbiol; 30:3320-3324.

Busch M, Wilber J, and Johnson P et al ., (1994): Impact of specimen handling and storage on detection of hepatitis C virus RNA Transfusion medicine .32:420-425.

Buti M, Sanchez-Avila F and Lurie Y et al ., (2002): Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. HEPATOLOGY;35:930-936.

Carlsson T, Reichard O and Norkrans G et al ., (2005): Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response . *Viral Hepat*;12:473-480.

Centers for Disease Control and prevention (2008): Hepatitis B virus Frequently asked question, division of viral hepatitis for health professionals. July 21, 2008.

Datta SD, Armstrong GL, Roome AJ et al., (2003): Blood exposure and hepatitis C virus infections among emergency groups .*Arch intern med*; 163:2605-2610.

Davis GL, Wong JB and McHutchison JG SC et al.,(2003): Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology*; 38:645–652.

De Franceschi L, Fattovich G and Turrini et al.,(2000):Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage .*Hepatology*; 31:997–1004.

De Franchesci L, Fattovich G and Turrini F et al (2000): Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C

virus infection: role of membrane oxidative damage .Hepatology ; 31: 997–1004.

Del Rio RA, Post AB and Singer ME(2006):Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy .HEPATOLOGY;44:1598-1606.

Dieterich DT, Wasserman R and Brau N et al.,(2003): Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus–infected patients receiving ribavirin plus interferon alfa .Am J Gastroenterol; 98:2491–2499.

Dixit V, Quan S ,Martin P et al., (1995): Evaluation of a novel serotyping system for hepatitis C virus: Strong correlation with standard genotyping methodologies. Clin Microbiol ;(33): 2978–2983 .

Dixit V, Quan S ,Martin P et al., (1995): Evaluation of a novel serotyping system for hepatitis C virus: Strong correlation with standard genotyping methodologies. Clin Microbiol ;(33): 2978–2983

Ferenci P, Fried MW and Shiffman ML et al ., (2005): Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin . Hepatol;43:425-433.

Fontaine H, Nalpas B and Poulet B et al ., (2001): Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. *Hum Pathol*;32:904-909.

Fried MW(2002): Side effects of therapy of hepatitis C and their management .*Hepatology*; 36(suppl 1):S237–S244.

Fried MW, Shiffman ML and Reddy KR et al (2002): Peginterferon alfa-2a plus ribavirin for patients with chronic hepatitis C virus infection .*N Engl J Med* ;347:975–982.

Gaeta GB, Precone DF, Felaco FM et al., (2002):Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in patients with chronic hepatitis C. *Aliment Pharmacol Ther.*; 16:1633-9.

GHANY and Sanderson S and Ploutz-Snyder R et al., (2009): *HEPATOLOGY*, Apr;49(4):1335-74.

Glaspy JA,(2003): Hematopoietic management in oncology practice Part 2 Erythropoietic factors .*Oncology (Huntingt)*; 17:1724–1739.

Hadziyannis SJ, Sette H Jr, Morgan TR, et al (2004): Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med*; 140:346-355.

Harris DR, Gonin R and Alter HJ et al ., (2001): The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. *Ann Intern Med*;134:120-124.

Hauser P (2004): Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression .*Gastroenterol Clin North Am*; 33:S35- S50.

Houghton M (1996) :Hepatitis C viruses Genetic organization of HCV genome Philadelphia, Lippincott - Raven,:1035-1058.

Jacobson IM, Brown RS and Freilich B et al ., (2007): Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. *HEPATOLOGY*;46: 971-981.

Jensen DM, Morgan TR and Marcellin P et al ., (2006): Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. *HEPATOLOGY*;43:954-960.

Khuroo MS, Khuroo MS and Dahab ST et al ., (2004): Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4 .*Aliment Pharmacol Ther*;20:931-938.

Kobayashi S, Takeda T and Enomoto M et al ., (2007):Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a

sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients .Liver Int; 27:186-191.

Koff, J, Younossi Z, Reddy KR et al ., (2004): Debate: hepatitis C with normal liver enzymes: to treat or not to treat. Am J Gastroenterology;99: 972-976 .

Kokka R , Sarrazin C, Teuber G et al., (2000): Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays .Hepatology,32:818-823 .

Kwon JH, et al (2009): Dose reduction in the treatment of hepatitis C: The Korean Journal of Internal Medicine Vol. 24, No. 3.

Lauer G , Walker B and Bruce D (2001): Hepatitis C virus infection. N Engl J Med; 345:41-52.

Lavanchy D and McMahon B(2000): Worldwide prevalence and prevention of hepatitis C In: Hepatitis C, Liang TJ, Hoofnagle JH, eds San Diego, Academic Press.185-202.

Levine RA, Sanderson SO and Ploutz-Snyder R et al ., (2006): Assessment of fibrosis progression in untreated irish women with chronic hepatitis C contracted from immunoglobulin anti-D .Clin Gastroenterol Hepatol;4:1271-1277.

Liang TJ, Rehermann B and Seeff LB et al ., (2000): Pathogenesis, natural history, treatment, and prevention of hepatitis C. *Ann Intern Med*; 132:296-305.

Lindahl K, Stahle L and Bruchfeld A (2005): High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. *HEPATOLOGY*;41:275-279.

Maddrey WC (1999):Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. *Semin Liver Dis*; 19:67–75.

Major ME and Feinstone SM (1997): The molecular virology of hepatitis C. *Hepatology*; 25:1527-1538.

Makoto and Trinh H and Garcia R et al., (2010): Differential Impact of Adherence to Pegylated Interferon and Ribavirin in the Treatment of Genotype 1 High Viral Titer Chronic Hepatitis C. *Hepatitis Research and Treatment Volume 2010*, Article ID 702748.

Manns MP, McHutchison JG and Gordon SC et al.,(2001): Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for

initial treatment of chronic hepatitis C: a randomised trial. *Lancet* ; 358:958–965.

Marcellin P, Lau GKK, Bonino F et al., (2004): Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. *N Engl J Med* 351: 1206-17.

Martin LM, Younossi ZM and Price L et al.,(2001):The impact of ribavirin-induced anemia on health-related quality of life. *Hepatology*; 34(suppl):600A Abstract.

McHutchison J(2004) :Understanding hepatitis C .*Am J manag care*; (10) :21-29.

McHutchison JG, Dusheiko G and Shiffman ML et al.,(2007): Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. *N Engl J Med*; 357:2227-2236.

McHutchison JG, Manns M and Patel K et al.,(2002): Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. *Gastroenterology*; 123:1061–1069.

Mizushima H, Hijikata M and Asabe S (1994): Two hepatitis C virus glycoprotein E2 products with different C termini *J. virol*; 68(10):6215-6222.

Mohamed MK(2004) : Epidemiology of HCV in Egypt .The Afro- Arab Liver Journal; 3(2)41-52.

Morris T,Robertson B and Gallagher M (1996):PCR detection in HCV RNA in serum by using TaqMan fluorogenic detection system .J Clin Microbiol;(34):2933-2936.

Nafeh M, Medhat A, Shehata M , et al ., (2000) : Hepatitis C in a community in Upper Egypt . Am J Trop Med Hyg; 63: 236 -241.

National Institutes of Health Consensus Development Conference Statement(2002): Management of hepatitis C: June 10-12, HEPATOLOGY;36:S3-S20

Nguyen MH, Trinh HN and Garcia R, Nguyen et al ., (2008): Higher rate of sustained virologic response in chronic hepatitis C genotype6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol;103:1131-1135.

NIH Consensus Development Panel (2002): National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: Hepatology 36(suppl 1):S3-S20.

Pawlotsky JM (2002): Molecular diagnosis of viral hepatitis .Gastroenterology; 122: 1554-1568.

Pawlotsky JM, Ben Yahia , et al., (2004):Immunologic disorders in C virus chronic active hepatitis :A prospective case control study. *Hepatology* ;19:841.

Pearlman BL, Ehleben C and Saifee S (2007):Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders .*HEPATOLOGY*;46:1688-1694.

Peck-Radosavljevic M, Wichlas M and Homoncik-Kraml M et al.,(2002): Rapid suppression of hematopoiesis by standard or pegylated interferon- alpha. *Gastroenterology* 2002; 123:141–151.

Pockros PJ, Shiffman ML and Schiff ER et al.,(2004): Epoetin alfa improves quality of life in anemic HCVinfected patients receiving combination therapy. *HEPATOLOGY*;40: 1450-1458.

Powell EE, Jonsson JR and Clouston AD (2005): Steatosis: co-factor in other liver diseases. *HEPATOLOGY*;42:5-13.

Purcell RH (1994): Hepatitis C virus In: *Encyclopedia of Virology* Webster RG, Granoff A, eds London, Academic Press Ltd, 569-574.

Putoi M, Airoidi M, Bruno et al ., (2002): Hepatitis B co –infection in human immuno -deficiency virus-infected subjects . *AIDS Rev*; 4:27-35.

Roberts EA and Yeung L (2002): Maternal –infant Transmission of hepatitis C virus infection. *Hepatology*; 36:106-113.

Romero-Gomez M, Del Mar Vilorio M and Andrade RJ et al ., (2005): Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology*;128:636-641.

Rossau R, Stuyver L ,Wyseur A et al., (1993): Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay, *J Gen. Virol*;74 :1093–1102.

Rumi, A Aghemo, GM Prati, et al., (2010): Randomized Study of Peginterferon-alpha2a Plus Ribavirin vs Peginterferon-alpha2b Plus Ribavirin in Chronic Hepatitis C. *Gastroenterology*138(1): 108-115.

Rustgi VK, Lee P and Finnegan S et al.,(2002): Safety and efficacy of recombinant human IL-11 (oprelvekin) in combination with interferon/ ribavirin in hepatitis C patients with thrombocytopenia. *Hepatology*; 36(4 Pt 2):361A. Abstract.

Sanchez-Tapias JM, Diago M and Escartin P et al ., (2006): Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment .*Gastroenterology*;131:451-460.

Sarbah SA and Younossi ZM (2000): Hepatitis C: *an update on the silent epidemic.*

Schiff E, Michael F and Willis C (2007): Hepatitis B and D Schiff'S disease of the liver .Anna L,Haris C and Francesco N.Tenth Edition ,part 2.29;751-771.

Schiff E, Michael F and Willis C (2007): Hepatitis C Schiff'S disease of the liver .Gary D.Tenth Edition ,part 2.30;819-834.

Seeff LB and Hoofnagle JH (2002) :National Institutes of Health Consensus Development Conference: management of hepatitis C.HEPATOLOGY;36(Suppl):S1-S2.

Shiffman ML, Di Bisceglie AM and Lindsay KL et al (2004): Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology ;141:451-455.

Shiffman ML, Salvatore J and Hubbard S et al.,(2007): Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. HEPATOLOGY ;46:371-379.

Singer ME and Younossi ZM (2001): Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med 3: 614-621 .

Soza A, Everhart JE and Ghany MG et al.,(2002): Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. HEPATOLOGY;36:1273-1279.

Strickland G, Elhefni H and Salman T (2002): Role of hepatitis C infection in chronic liver disease in Egypt .Am J Trop Med Hyg; 67(4): 436-42 .

Sulkowski M.(2003): Managing the hematologic complications of interferon/ribavirin Clinical Care Options for Hepatitis Annual Update .IMedOptions, Milford, Mass; 101-122.

Tedder, R.S and Briggs, M et al(1999) - Detection of hepatitis C viral sequences in body fluids in blood donations by “nested” polymerase chain reaction and prediction of infectivity. Lancet, 335: 1419-1422.

Thomas DL and Seeff LB (2005): Natural history of hepatitis C.Clin Liver Dis;9:383-398, vi.

Tong MJ, el-Farra NS and Reikes AR(1995): Clinical outcomes after transfusion- associated hepatitis C. N Engl J Med;332:1463-1466.

Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al (2004): Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med; 351:438-450.

Van Thiel DH, Faruki H and Friedlander L et al.,(1995): Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology; 42:907–912.

Waked I ,Saleh S, Moustafa M et al., (1995) :High prevalence of hepatitis C in Egyptian patients with chronic liver diseases .*Gut*; 37:(1)105-107.

Wakil A and Merezban Z (2006): Hepatitis C in Egypt In Egypt today magazine .HCV adovacte ,2006.*WWW HCV adovacte.org*.

Wiese M, Grungreiff K and Guthoff W et al ., (2005): Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany: a 25-year multicenter study . *Hepatology*;43:590-598.

Wong S, Kaita K and Gauthier T et al (1996): A comparative trial of recombinant interferon alpha 2a versus alpha 2b on myelosuppression in healthy adult volunteers . *Hepatogastroenterology* ;43:301-305.

Wong S, Kaita K and Gauthier T et al (1996): A comparative trial of recombinant interferon alpha 2a versus alpha 2b on myelosuppression in healthy adult volunteers. *Hepatogastroenterology* ;43:301-305.

World Health Organization (1999): Global surveillance and control of hepatitis C Report of a WHO Consultation organized in Collaboration with the Viral Hepatitis Prevention Board. *Hepatology*; 6: 35-47.

World Health Organization (2007): Hepatitis C: Key facts WHO media center November 2007 No164

<http://www.who.int/mediacentre/factsheets/fs204/en/> Accessed on 24, 2007.

World Health Organization (2008): Hepatitis B : Key facts WHO media center August 2008 No 204:1-4
<http://www.who.int/mediacentre/factsheets/fs204/en/> Accessed on August 2008 .

Yano M, Kumada H and Kage M et al ., (1996): The long-term pathological evolution of chronic hepatitis C. HEPATOLOGY;23:1334-1340.

Younossi , Janusp ONG, AND Zobair M., et al.(2004): Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: Cleveland clinic journal of medicine volume 71 supplement 3 may.

Younossi ZM, Ong JP and Collantes R, et al.,(2004): Darbepoetin alfa for ribavirin- induced anemia in patients with chronic hepatitis C treated with pegylated interferon and ribavirin: a preliminary analysis .Gastroenterology; 126(suppl 2). Abstract.

Yu JW, Wang GQ and Sun LJ(2007): Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. Gastroenterol Hepatol;22:832-836.

Zekri AR,Bahanassy AA,Ramadan AS et al .,(2001):HCV in Egyptian patients.Infection;29(1)24-36.